CoChat
Sign Up
Cited by 146Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsGenetic and Kidney Cyst Diseases

Polycystic Ovary Syndrome and Risk for Long-Term Diabetes and Dyslipidemia

Open access
Wang, Erica T., Calderon-Margalit, Ronit, Cedars, Marcelle I., Daviglus, Martha L., Merkin, Sharon S., Schreiner, Pamela J., Sternfeld, Barbara, Wellons, Melissa +5 more·2011·Obstetrics & Gynecology
DOI 10.1097/aog.0b013e31820209bbPMC PMC3060760
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To estimate whether women aged 20-32 years who fulfilled National Institutes of Health criteria for polycystic ovary syndrome (PCOS) would be at higher risk for subsequent development of incident diabetes, dyslipidemia, and hypertension, and to estimate whether normal-weight women with PCOS would have the same degree of cardiovascular risk as overweight women with PCOS. METHODS: We estimated the association of PCOS with incident diabetes, dyslipidemia, and hypertension over a period of 18 years among 1,127 white and African-American women in the Coronary Artery Risk Development in Young Adults cohort. We classified women at baseline (ages 20-32 years) based on self-reported symptoms and serum androgen measures using National Institutes of Health PCOS criteria. We estimated the association of PCOS and subsequent cardiovascular risk factors, independent of baseline body mass index (BMI), using multivariable logistic regression. Additionally, among 746 women with a second assessment of PCOS at ages 34-46 years, we estimated the association of persistent PCOS with cardiovascular risk factors. RESULTS: Of 1,127 women, 53 (4.7%) met criteria for PCOS at ages 20-32 years. Polycystic ovary syndrome was associated with a twofold higher odds of incident diabetes (23.1% compared with 13.1%, adjusted odds ratio [AOR] 2.4, confidence interval [CI] 1.2-4.9) and dyslipidemia (41.9% compared with 27.7%, AOR 1.9, CI 1.0-3.6) over the course of 18 years; the association with incident hypertension was not significant (26.9% compared with 26.3%, AOR 1.7, CI 0.8-3.3). Normal-weight women with PCOS (n=31) had a threefold higher odds of incident diabetes compared with normal-weight women without PCOS (AOR 3.1, CI 1.2-8.0). Compared with those without PCOS, women with persistent PCOS (n=11) had the highest odds of diabetes (AOR 7.2, CI 1.1-46.5). CONCLUSION: Polycystic ovary syndrome is associated with subsequent incident diabetes and dyslipidemia, independent of BMI. Diabetes risk may be greatest for women with persistent PCOS symptoms. LEVEL OF EVIDENCE: II.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aog.0b013e31820209bb

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PCOS increases the risk of type 2 diabetes and obesity in women, thus in utero androgen exposure may both directly and indirectly have an impact on adiposity in later life.

    “PCOS increases the risk of type 2 diabetes and obesity in women, thus in utero androgen exposure may both directly and indirectly have an impact on adiposity in later life [129, 130].”

    From Developmental programming of offspring adipose tissue biology and obesity risk (2021) · cites this paper as [130]

    The Results report higher odds of incident diabetes in women with PCOS, and the Introduction describes an association between PCOS and obesity. The paper does not establish that PCOS increases the risk of developing obesity; it also does not examine in utero androgen exposure or later-life adiposity, which the citing sentence presents as an inference. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 19

  1. [3]Legro RS Kunselman AR Dunaif A Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome Am J Med 2001 Dec 1 111 8 607 613 11755503
  2. [4]Lo JC Feigenbaum SL Yang J Pressman AR Selby JV Go AS Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome J Clin Endocrinol Metab 2006 Apr 91 4 1357 1363 16434451
  3. [5]Taponen S Martikainen H Jarvelin MR Sovio U Laitinen J Pouta A Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study J Clin Endocrinol Metab 2004 May 89 5 2114 2118 15126528
  4. [6]Wild S Pierpoint T McKeigue P Jacobs H Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study Clin Endocrinol (Oxf) 2000 May 52 5 595 600 10792339
  5. [7]Lunde O Tanbo T Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15–25 years after ovarian wedge resection Gynecol Endocrinol 2007 Dec 23 12 704 709 18075845
  6. [8]Winters SJ Talbott E Guzick DS Zborowski J McHugh KP Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome Fertil Steril 2000 Apr 73 4 724 729 10731532
  7. [9]Elting MW Korsen TJ Rekers-Mombarg LT Schoemaker J Women with polycystic ovary syndrome gain regular menstrual cycles when ageing Hum Reprod 2000 Jan 15 1 24 28 10611183
  8. [10]Friedman GD Cutter GR Donahue RP Hughes GH Hulley SB Jacobs DR Jr CARDIA: study design, recruitment, and some characteristics of the examined subjects J Clin Epidemiol 1988 41 11 1105 1116 3204420
  9. [11]Pearlman WH Crepy O Murphy M Testosterone-binding levels in the serum of women during the normal menstrual cycle, pregnancy, and the post-partum period J Clin Endocrinol Metab 1967 Jul 27 7 1012 1018 6028274
  10. [12]Sidney S Jacobs DR Jr Haskell WL Armstrong MA Dimicco A Oberman A Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study Am J Epidemiol 1991 Jun 15 133 12 1231 1245 2063831
  11. [13]Folsom AR Burke GL Ballew C Jacobs DR Jr Haskell WL Donahue RP Relation of body fatness and its distribution to cardiovascular risk factors in young blacks and whites. The role of insulin Am J Epidemiol 1989 Nov 130 5 911 924 2683750
  12. [14]Friedewald WT Levy RI Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 1972 Jun 18 6 499 502 4337382
  13. [17]Burghen GA Givens JR Kitabchi AE Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease J Clin Endocrinol Metab 1980 Jan 50 1 113 116 7350174
  14. [18]Corbould A Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome? Diabetes Metab Res Rev 2008 Oct 24 7 520 532 18615851
  15. [19]Holte J Gennarelli G Berne C Bergh T Lithell H Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? Hum Reprod 1996 Jan 11 1 23 28 8671152
  16. [20]Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Hum Reprod 2004 19 41 14688154
  17. [21]Salley KE Wickham EP Cheang KI Essah PA Karjane NW Nestler JE Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society J Clin Endocrinol Metab 2007 Dec 92 12 4546 4556 18056778
  18. [22]Sharma ST Wickham EP 3rd Nestler JE Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis Endocr Pract 2007 Jul–Aug 13 4 373 379 17669713
  19. [23]Pedersen SD Brar S Faris P Corenblum B Polycystic ovary syndrome: validated questionnaire for use in diagnosis Can Fam Physician 2007 Jun 53 6 1042 1047 1 17872783 PMC1949220

Cited by

Sorted by citations

Authors
Wang, E. T., Calderon-Margalit, R., Cedars, M. I., Daviglus, M. L., Merkin, S. S., Schreiner, P. J., Sternfeld, B., Wellons, M., Schwartz, S. M., Lewis, C. E., Williams, O. D., Siscovick, D. S., & Bibbins-Domingo, K.
Affiliations
  • Northwestern University (US)
  • University of California, San Francisco (US)
  • University of California, Los Angeles (US)
  • University of Minnesota (US)
  • Kaiser Permanente (US)
  • University of Alabama at Birmingham (US)
  • University of Washington (US)
Corresponding author
Wang, Erica T.
ORCID
Venue
Obstetrics & Gynecology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-01
Volume
117
Issue
1
Pages
6-13
ISSN
0029-7844 (ISSN-L)
DOI
10.1097/aog.0b013e31820209bb
PMC
PMC3060760
OpenAlex
W2011888336
Cited by
146
References
3
Citations by year
2026: 4 · 2025: 3 · 2024: 7 · 2023: 10 · 2022: 20 · 2021: 20 · 2020: 6 · 2019: 11 · 2018: 14 · 2017: 7 · 2016: 4 · 2015: 11 · 2014: 9 · 2013: 4 · 2012: 7
FWCI
7.62
Type
journal article
Language
en
Open access
Locations
  • Obstetrics and Gynecology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (n01hc95095-66-0-1, n01hc48050-59-0-1, n01hc48048-58-0-1, n01hc045134-008, n01hc48047-55-0-1, n01hc45205-9-0-0, n01hc005187-000, n01hc48049-61-0-1, n01hc45204-11-0-1)
  • National Heart, Lung, and Blood Institute (N01HC48050, N01-HC045134, N01 HC 95095, N01 HC045205, N01 HC048048, N01-HC05187, N01-HC-048049, N01 HC045204, N01-HC- 45204, N01 HC095095, N01 HC048050, N01-HC48048, N01-HC-45205, N01 HC005187, N01-HC-48-049, N01 HC048047, N01-HC-480-47, R01HL065622, R01HL065611)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Keywords
polycystic ovary syndrome, type 2 diabetes, dyslipidemia, hypertension, cardiovascular risk, body mass index, young women, Coronary Artery Risk Development in Young Adults, androgens, long-term risk factors, African American women, white women, normal-weight women, overweight women, hyperinsulinemia, insulin resistance
MeSH terms
Adult, Diabetes Mellitus, Female, Humans, Hypertension, Polycystic Ovary Syndrome, Prospective Studies, United States, Dyslipidemias, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review